Anti-tumour necrosis factors therapy for severe inflammatory arthritis: Two years of experience in Northern Ireland

Ulster Medical Journal

Volumn 71, Issue 2, 2002, Pages 101-105

  Cairns, A P ^a   Taggart, A J ^a  

^a MUSGRAVE PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG USE; FEMALE; GASTROENTERITIS; HOSPITALIZATION; HUMAN; IDIOPATHIC DISEASE; INFECTION; INFECTION SENSITIVITY; JUVENILE RHEUMATOID ARTHRITIS; LOBAR PNEUMONIA; LUNG ALVEOLITIS; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MILIARY TUBERCULOSIS; OTITIS MEDIA; PATHOGENESIS; RHEUMATOID ARTHRITIS; SCHOOL CHILD; TREATMENT OUTCOME; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHILD; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036863114     PISSN: 00416193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Silman A J. Rheumatoid artritis. In: Silman A J, Horchberg M C, editors. Epidemiology of the rheumatic diseases. Oxford: Oxford University Press; 1993.
2. Hulsmans U M, Jacobs J W, van der Heijde D M, van Albada-Kuipers G A, Schenk Y, BijIsma J W. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000; 43(9): 1927-40.
3. van der Horst-Bruinsma I E, Speyer I, Visser H, Breedveld F C, Hazes J M. Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. Br J Rheumatol 1998; 37(10): 1084-8.
4. Fries J F, Williams C A, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996; 39(4): 616-22.
5. Mitchell D M, Spitz P W, Young D Y, Bloch D A, McShane D J, Fries J F. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 29(6): 706-14.
6. Husby G, Williams R C Jr. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1988; 1(4): 363-71.
7. Maini R, St Clair E W, Breedveld F, Furst D, Kalder J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354(9194): 1932-9.
8. Lipsky P E, van der Heijde D M, St Clair E W, Furst D E, Breedveld F C, Kalden J R, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343(22): 1594-602.
9. Bathon J M, Martin R W, Fleischmann R M, Tesser J R, Schiff M H, Keystone E C, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343(22): 1586-93.
10. Lovell D J, Giannini E H, Reiff A, Cawkwell G D, Silverman E D, Nocton J J, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342(11): 763-9.
11. Guidelines for prescribing TNF blockers in adults with rheumatoid arthritis. Report of a working party of the British Society for Rheumatology, London. April 2000. Available from: URL: http:// www.msecportal.org/go/msecportal/guest/homepageguest.jsp?society=bsr
12. Prevoo M L, van't Hof M A, Kuper H H, van Leeuwen M A, van de Putte L B, van Riel P L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38(1): 44-8.
13. Mease P J, Goffe B S, Metz J, VanderStoep A, Finck B, Burge D J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356(9227): 385-90.
14. Brandt J, Haibel H, Cornely D, Golder W, Goazalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43(6): 1346-52.
15. Garrett S, Jenkinson T, Kennedy L G, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21(12): 2286-91.
16. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. NICE technology appraisal guidance; 36. The National Institute for Clinical Excellence, London. March 2002. Available from: URL: http://www.nice.org.uk/pdf/ra-pdf.pdf
17. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. NICE technology appraisal guidance 35. The National Institute for Clinical Excellence, London. March 2002. Available from: URL: http://www.nice.org.uk/pdf/jia-pdf.pdf
18. Bresnihan B, Alvaro-Gracia J M, Cobby M, Doherty M, Domljanm, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41(12): 2196-204.
19. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46(2): 328-46.